Chengyou Jia, Vivian Medina, Chenchang Liu, Lina He, Daohai Qian, Taojian Tu, Curtis T. Okamoto, Bangyan L. Stiles – 1 April 2017 – Liver kinase B 1 (LKB1 or STK11) and phosphatase and tensin homologue deleted on chromosome 10 (PTEN) are two tumor suppressors that regulate the mammalian target of rapamycin signaling pathway. Deletion studies show that loss of either Lkb1 (Lkb+/–) or Pten (PtenloxP/loxP; Alb‐Cre+) leads to liver injury and development of hepatocarcinoma. In this study, we investigated the crosstalk of LKB1 and PTEN loss during tumorigenesis and liver development.

Ewan Forrest – 1 April 2017

Eva Herrmann, Victor de Lédinghen, Christophe Cassinotto, Winnie C.‐W. Chu, Vivian Y.‐F. Leung, Giovanna Ferraioli, Carlo Filice, Laurent Castera, Valérie Vilgrain, Maxime Ronot, Jérôme Dumortier, Aymeric Guibal, Stanislas Pol, Jonel Trebicka, Christian Jansen, Christian Strassburg, Rongqin Zheng, Jian Zheng, Sven Francque, Thomas Vanwolleghem, Luisa Vonghia, Emanuel K.

James Fung, Tiffany Wong, Kenneth Chok, Albert Chan, Tan‐To Cheung, Jeff Wing‐Chiu Dai, Sui‐ling Sin, Ka‐Wing Ma, Kelvin Ng, Kevin Tak‐Pan Ng, Wai‐Kay Seto, Ching‐Lung Lai, Man‐Fung Yuen, Chung‐Mau Lo – 31 March 2017 – Long‐term antiviral prophylaxis is required to prevent hepatitis B recurrence for patients with chronic hepatitis B after liver transplantation. We determined the long‐term outcome of 265 consecutive chronic hepatitis B liver transplant recipients treated with entecavir monotherapy without hepatitis B immune globulin.

Chibuzo Iloabuchi, Amanda Stover, Pragya Rai, Yifan Zhang, Khalid M. Kamal – 31 March 2017

James Fung, Tiffany Wong, Kenneth Chok, Albert Chan, Tan‐To Cheung, Jeff Wing‐Chiu Dai, Sui‐ling Sin, Ka‐Wing Ma, Kelvin Ng, Kevin Tak‐Pan Ng, Wai‐Kay Seto, Ching‐Lung Lai, Man‐Fung Yuen, Chung‐Mau Lo – 31 March 2017 – Long‐term antiviral prophylaxis is required to prevent hepatitis B recurrence for patients with chronic hepatitis B after liver transplantation. We determined the long‐term outcome of 265 consecutive chronic hepatitis B liver transplant recipients treated with entecavir monotherapy without hepatitis B immune globulin.

Mitchell L. Shiffman, Nadege T. Gunn – 30 March 2017

Samer Tohme, Hamza O. Yazdani, Yao Liu, Patricia Loughran, Dirk J. van der Windt, Hai Huang, Richard L. Simmons, Sruti Shiva, Sheng Tai, Allan Tsung – 30 March 2017 – The ability of cancer cells to survive and grow under hypoxic conditions has been known for decades, but the mechanisms remain poorly understood. Under certain conditions, cancer cells undergo changes in their bioenergetic profile to favor mitochondrial respiration by activating the peroxisome proliferator–activated receptor gamma coactivator 1 alpha (PGC‐1α) and up‐regulating mitochondrial biogenesis.

Marco Cassano, Sandra Offner, Evarist Planet, Alessandra Piersigilli, Suk Min Jang, Hugues Henry, Markus B. Geuking, Catherine Mooser, Kathy D. McCoy, Andrew J. Macpherson, Didier Trono – 30 March 2017 – Hepatocellular carcinoma (HCC) represents the fifth‐most common form of cancer worldwide and carries a high mortality rate attributed to lack of effective treatment. Males are 8 times more likely to develop HCC than females, an effect largely driven by sex hormones, albeit through still poorly understood mechanisms.

Young‐Suk Lim, Yung Sang Lee, Geum‐Youn Gwak, Kwan Soo Byun, Yoon Jun Kim, Jonggi Choi, Jihyun An, Han Chu Lee, Byung Chul Yoo, So Young Kwon – 30 March 2017 – Combination therapy has been recommended for the treatment of patients harboring multiple drug‐resistant hepatitis B virus (HBV). However, we recently demonstrated that monotherapy with tenofovir disoproxil fumarate (TDF) for 48 weeks displayed noninferior efficacy to TDF plus entecavir (ETV) combination therapy in patients with HBV resistant to multiple drugs, including ETV and adefovir.